OSE Immunotherapeutics Presents New Data on Anti-SIRPa (Effi-DEM), the Checkpoint Inhibitor blocking Pro-Tumor and Suppressor Myeloid Cells at “Advances in Immuno-Oncology Congress,” London, May 15-16, 2017

NANTES, France, May 15, 2017 (GLOBE NEWSWIRE) — OSE Immunotherapeutics SA(ISIN:FR0012127173) (Mnémo:OSE) announced today that the Company presented in oral session significant data on Selective Anti-SIRPa OSE-172 (Effi-DEM), at the “2ndAnnual Advances in Immuno-Oncology Congress” in London on May 15, 2017.